| At baseline | After bolus application | At end of treatment period | |||
---|---|---|---|---|---|---|
 | Placebo | Antithrombin | Placebo | Antithrombin | Placebo | Antithrombin |
Prothrombin time (%) | 70 (38–95) | 60 (38–103) | 60 (39–84) | 60 (38–82) | 77 (5–10) | 64 (5–9) |
Activated partial thromboplastin time (s) | 42 (27–53) | 46 (33–60) | 44 (32–67) | 53 (34–77) | 44 (29–74) | 47 (34–95) |
Fibrinogen (mg/dl) | 587 (262–821) | 557 (229–841) | 595 (283–770) | 505 (313–704) | 622 (115–842) | 538 (200–868) |
Platelet count (1,000/ml) | 225 (86–581) | 179 (71–742) | 170 (81–358) | 154 (61–730) | 199 (63–418) | 115 (14–475) |
Antithrombin (%) | 68 (31–113) | 55 (27–99) | 54 (22–108) | 110* (43–350) | 86 (29–87) | 141* (110–149) |
Reaction time (mm) | 7 (6–15) | 9 (6–16) | 8 (5–15) | 11 (7–25) | 8 (5–19) | 11 (8–18) |
Coagulation time (mm) | 3 (2–4) | 3 (2–8) | 3 (2–4) | 3 (2–7) | 2 (1–8) | 4 (3–10) |
Alpha angle (°) | 74 (64–80) | 71 (50–80) | 69 (64–81) | 70 (36–79) | 76 (43–81) | 64 (46–76) |
Maximum amplitude (mm) | 69 (57–79) | 66 (49–81) | 66 (60–74) | 70 (49–83) | 71 (38–82) | 72 (38–82) |
Abciximab maximum amplitude (mm) | 29 (15–49) | 29 (13–49) | 29 (23–45) | 28 (12–45) | 33 (14–48) | 31 (7–48) |